Archemix Going Public Via Reverse Merger with NitroMed
Archemix Corp., a Cambridge, Mass.-based developer of aptamer-based therapeutics, has agreed to go public via a reverse merger with NitroMed Inc. (Nasdaq: NTMD). Archemix shareholders will own 70% of the combined company, while NitroMed shareholders will hold the remainder. Archemix earlier this year withdrew an IPO offering, after having raised around $135 million in VC funding from firms like Atlas Venture (13.9% stake), Prospect Venture Partners (13.9%), Highland Capital Parnters (13.2%), SV Life Sciences (11.6%), KGaA (11.3%), Rho Ventures (9.6%) and Care Capital (5.3%).
19 November 2008•9 mins read
